Mabylon AG
Treatment of Neurological Diseases and Allergies
Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies and neurodegenerative diseases. The company was spawned from the research of Prof. Adriano Aguzzi and his colleagues at the University of Zurich (UZH) and the University Hospital of Zurich (USZ).
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
22.05.2026
Swiss biotechs progress across cardiology, oncology and allergy clinical programs (startupticker.ch)
30.04.2026
Three Swiss deep tech startups secure Eureka funding (startupticker.ch)
11.12.2025
Biotechs advance therapies against bacterial infections and peanut allergies (startupticker.ch)
12.08.2025
Mabylon raises CHF 30 million to fight allergies with human-derived antibodies (startupticker.ch)
30.09.2024
Financial support sets Mabylon on track to advance allergy treatments (startupticker.ch)
No milestones
No Jobs
No videos and documents
Mabylon AG
Treatment of Neurological Diseases and Allergies
Headquarter:
Schlieren
Foundation Date:
December 2011
Technology:
- Biotech